Lake Street Capital Markets Starts Optinose (OPTN) at Buy, 'potential label-expanding FDA approval in December could triple the TAM'

Lake Street Capital Markets analyst Thomas Flaten initiates coverage on Optinose (NASDAQ: OPTN) with a Buy rating and a price target of $3.00.

The analyst comments "2023 is a reset year for OPTN and shares are down 68% over the last 12 months. A potential label-expanding FDA approval in December could triple the TAM and drive renewed revenue growth (47% in 2024, 43% in 2025) by building on its existing track record ($76M in 2022 sales). We believe this is a good entry point for investors. Initiating coverage with a Buy and $3 PT"

For an analyst ratings summary and ratings history on Optinose click here. For more ratings news on Optinose click here.

Shares of Optinose closed at $1.30 yesterday.

You May Also Be Interested In

• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy